## **Providing high-quality healthcare** services to even more people

As the leading generic drug company, we strive to provide a stable supply of high-quality generic drugs and support the healthy lives of people. We are also taking on the challenge of evolving into a general healthcare company by developing new businesses.



Contributing to extension of healthy life expectancy / Developing talent

**Business** results\*(Output)

Revenue ¥200.3 billion

Operating profit ¥17.0 billion

ROE 6.5%

**Production volume** 

16.6

billion tablets (Japan business)

2.9 billion tablets (U.S. business)

**New products** 

 $23_{\,products}$ (Japan business)

2 products (U.S. business)

Patent applications 32

\*actual for FY2022

Value provided to society (Outcome)

Improving healthcare access

15.0 billion tablets

Contributing to healthcare financing Amount of reduction in healthcare costs

¥280.9 billion (Japan business)

**Contributing to extension** of healthy life expectancy

Personal health record (PHR) management app Used by more than

**Developing talent** 

Employee education and training expenses (Sawai Group in Japan)

¥85.00 million

respect for human rights / Corporate governance